Hypersecretion of gastric inhibitory polypeptide induced by glucose ingestion in diabetes mellitus. 1981

J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura

The response to plasma immunoreactive gastric inhibitory polypeptide (GIP) to oral glucose loading was determined in 10 normal subjects, 10 patients with mild diabetes mellitus, and 10 patients with moderate to severe diabetes mellitus. In normal subjects the mean fasting GIP was 167 +/- 17 pg/ml which rose significantly after glucose loading, reaching the peak value of 513 +/- 44 pg/ml at 30 min. In mild diabetic patients, fasting plasma GIP was not significantly different from that in normal subjects. However, the mean peak GIP level following glucose loading was 683 +/- 71 pg/ml, significantly higher than that in normal subjects (p less than 0.05). In moderate and severe diabetics, oral glucose loading caused an abrupt rise in plasma GIP from the basal level of 304 +/- 31 pg/ml to the peak of 870 +/- 63 pg/ml occurring at 30 min, both of which were significantly higher than the corresponding values in normal subjects (p less than 0.01). These results suggest that GIP response to oral glucose loading is enhanced in diabetic patients in proportion to the degree of their glucose intolerance.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005749 Gastric Inhibitory Polypeptide A gastrointestinal peptide hormone of about 43-amino acids. It is found to be a potent stimulator of INSULIN secretion and a relatively poor inhibitor of GASTRIC ACID secretion. Glucose-Dependent Insulinotropic Peptide,Gastric-Inhibitory Polypeptide,Glucose Dependent Insulinotropic Peptide,Glucose-Dependent Insulin-Releasing Peptide,Glucose Dependent Insulin Releasing Peptide,Inhibitory Polypeptide, Gastric,Insulin-Releasing Peptide, Glucose-Dependent,Insulinotropic Peptide, Glucose-Dependent,Peptide, Glucose-Dependent Insulin-Releasing,Peptide, Glucose-Dependent Insulinotropic,Polypeptide, Gastric Inhibitory,Polypeptide, Gastric-Inhibitory
D005768 Gastrointestinal Hormones HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs. Enteric Hormone,Enteric Hormones,Gastrointestinal Hormone,Intestinal Hormone,Intestinal Hormones,Hormone, Enteric,Hormone, Gastrointestinal,Hormone, Intestinal,Hormones, Enteric,Hormones, Gastrointestinal,Hormones, Intestinal
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
June 1977, Diabetes,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
May 1981, The Journal of clinical endocrinology and metabolism,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
June 1984, The Journal of clinical endocrinology and metabolism,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
August 1982, The Journal of clinical endocrinology and metabolism,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
January 1985, Diabetes care,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
October 1976, Diabetes,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
August 1975, The Journal of clinical endocrinology and metabolism,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
March 1983, The Tohoku journal of experimental medicine,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
March 1985, Acta physiologica Scandinavica,
J Takemura, and Y Seino, and K Tsuda, and S Seino, and M Ikeda, and H Sakurai, and H Imura
October 1995, Acta diabetologica,
Copied contents to your clipboard!